According to the Complaint, Cambrex Corporation is the leading small molecule company that provides drug substance, drug product, and analytical services across the entire drug life cycle.

This action stems from a proposed transaction announced on August 7, 2019, pursuant to which Cambrex will be acquired by Catalog Intermediate Inc. and Catalog Merger Sub Inc., which are controlled by investment funds advised by Permira Advisers LLC.

On August 7, 2019, Cambrex’s Board of Directors caused the Company to enter into an agreement and plan of merger with Permira. Pursuant to the terms of the Merger Agreement, Cambrex’s stockholders will receive $60.00 in cash for each share of Cambrex common stock they own.

On September 23, 2019, Defendants filed a Proxy Statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction, which scheduled a stockholder vote on the Proposed Transaction for October 23, 2019. The Complaint alleges that the Proxy Statement omits material information with respect to the Proposed Transaction, which renders the Proxy Statement false and misleading.

This case was voluntarily dismissed on May 15, 2020.